2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 564

Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis
Abstract Number: 1597

Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Abstract Number: 680

Variability over Time in Patient-Reported Outcome Measures in Patients with Ankylosing Spondylitis
Abstract Number: 92

Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
Abstract Number: 59

Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity
Abstract Number: 2388

Variations in Hip Morphology Are Associated with Hip Symptoms: Preliminary Results from a Large Community-Based Cohort
Abstract Number: 2694

Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Abstract Number: 2429

Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety
Abstract Number: 2799

Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease
Abstract Number: 1259

Verification of Haptoglobin and Von Willebrand Factor As Potential Biomarkers of Knee Osteoarthritis Using a Targeted Proteomics Approach in Serum
Abstract Number: 2065

Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Abstract Number: 364

Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study
Abstract Number: 2392

Vibration Perception Threshold and Hip Osteoarthritis in Multicenter Ostoearthritis Study
Abstract Number: 1679

Vicm Is a Novel Biomarker of Macrophage Activity Evaluated in a Phase IIb Clinical Trial of Mavrilimumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].